Eli Lilly’s October 2024 evaluation agreement with Peptron for SmartDepot—an ultrasonic spray-dried PLGA microsphere sustained-release platform—remains limited to non-exclusive internal R&D feasibility testing on select peptides, with any commercial licensing or technology transfer explicitly optional. Nearly two years of joint work, recently expanded to CNS candidates, has yielded no binding deal despite data sharing, while Lilly retains easy termination rights and has shifted priority toward oral GLP-1 candidates like orforglipron. The fast-approaching October 7 resolution date, combined with Lilly’s parallel delivery partnerships and absence of recent catalysts, underpins trader consensus that a definitive license is improbable in the remaining window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 evaluation agreement with Peptron for SmartDepot—an ultrasonic spray-dried PLGA microsphere sustained-release platform—remains limited to non-exclusive internal R&D feasibility testing on select peptides, with any commercial licensing or technology transfer explicitly optional. Nearly two years of joint work, recently expanded to CNS candidates, has yielded no binding deal despite data sharing, while Lilly retains easy termination rights and has shifted priority toward oral GLP-1 candidates like orforglipron. The fast-approaching October 7 resolution date, combined with Lilly’s parallel delivery partnerships and absence of recent catalysts, underpins trader consensus that a definitive license is improbable in the remaining window.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 evaluation agreement with Peptron for SmartDepot—an ultrasonic spray-dried PLGA microsphere sustained-release platform—remains limited to non-exclusive internal R&D feasibility testing on select peptides, with any commercial licensing or technology transfer explicitly optional. Nearly two years of joint work, recently expanded to CNS candidates, has yielded no binding deal despite data sharing, while Lilly retains easy termination rights and has shifted priority toward oral GLP-1 candidates like orforglipron. The fast-approaching October 7 resolution date, combined with Lilly’s parallel delivery partnerships and absence of recent catalysts, underpins trader consensus that a definitive license is improbable in the remaining window.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 evaluation agreement with Peptron for SmartDepot—an ultrasonic spray-dried PLGA microsphere sustained-release platform—remains limited to non-exclusive internal R&D feasibility testing on select peptides, with any commercial licensing or technology transfer explicitly optional. Nearly two years of joint work, recently expanded to CNS candidates, has yielded no binding deal despite data sharing, while Lilly retains easy termination rights and has shifted priority toward oral GLP-1 candidates like orforglipron. The fast-approaching October 7 resolution date, combined with Lilly’s parallel delivery partnerships and absence of recent catalysts, underpins trader consensus that a definitive license is improbable in the remaining window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions